Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

Autor: Stefano Fagiuoli, Paolo Fabris, M. Milan, Diego Martines, Salvatore Lobello, Andrea Buda, S. Boninsegna, L. Scribano
Přispěvatelé: Milan, M, Boninsegna, S, Scribano, L, Lobello, S, Fagiuoli, S, Fabris, P, Buda, A, Martines, D
Rok vydání: 2011
Předmět:
Male
Time Factors
Hepacivirus
Disease
Logistic regression
Gastroenterology
Polyethylene Glycols
chemistry.chemical_compound
Risk Factors
Fibrosis
Pegylated interferon
Secondary Prevention
Medicine
Relapse
virus diseases
General Medicine
Middle Aged
Viral Load
Recombinant Proteins
Infectious Diseases
HCV
RNA
Viral
Drug Therapy
Combination
Female
medicine.drug
Adult
Microbiology (medical)
medicine.medical_specialty
Genotype
Interferon alpha-2
Antiviral Agents
Viral kinetic
HCV
Predictors
Relapse
Viral kinetics
Internal medicine
Ribavirin
Humans
Viral kinetics
Retrospective Studies
Hepatitis
Analysis of Variance
Predictors
business.industry
Interferon-alpha
Hepatitis C
Chronic
medicine.disease
Virology
digestive system diseases
Discontinuation
Logistic Models
chemistry
Steatosis
business
Predictor
Zdroj: Infection. 40:173-179
ISSN: 1439-0973
0300-8126
Popis: Background Pegylated interferon (PEG-IFN) and ribavirin is the most effective treatment for chronic hepatitis C virus (HCV) hepatitis, but the rate of sustained virological response (SVR) remains approximately 50%, and 15-20% of all treated patients have a virological relapse after completing the treatment. Studies on the SVR have failed to discriminate between non-responders and relapsers. Aims To identify the risk factors for relapse among patients with an end-of-treatment response (ETR). Methods We retrospectively analyzed 281 patients consecutively treated with PEG-IFN and ribavirin with a follow- up period of at least 24 weeks. The baseline details collected on each patient included demographic data, histological features, and biochemical profiles. Results Forty-six patients (16.4%) relapsed during the first 6 months of follow-up after discontinuing the therapy. Relapser patients were significantly older, had more steatosis, fibrosis, and showed significantly lower rapid virological response (RVR) rates compared with SVR patients. By logistic regression analysis, only the absence of RVR was found to be significantly associated with relapses in both subgroups of patients with genotypes 1 and 4 (p.004) and those with genotypes 2 and 3 (p.006). Severe fibrosis was also predictive of relapsing disease, but only for genotypes 2 and 3 patients (p.003). During the treatment, serum HCV-RNA decreased more rapidly in patients with SVR compared to non-responder and relapser patients (p.001). Interestingly, relapser patients exhibited an intermediate serum HCV-RNA decay during the first 4 weeks of therapy. Conclusion Among HCV patients treated with PEG-IFN and ribavirin, the absence of RVR was the most important independent predictor of relapse, independent of the HCV genotype. In the subgroup of genotypes 2 and 3 patients, the severity of fibrosis was also an important factor associated with the relapse rate.
Databáze: OpenAIRE
Externí odkaz: